SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBridgepoint Regulatory News (BPT)

Share Price Information for Bridgepoint (BPT)

Share Price is delayed by 15 minutes
Get Live Data
244.40    5.60 (2.35%)
Bid:
244.60
Ask:
245.00
Spread: 0.40 (0.164%)
Market Cap: £2.14b
BPT Live PriceLast checked at - London Stock Exchange

Intraday Bridgepoint Share Chart

Directorate Change

23 Nov 2022 07:00

RNS Number : 2685H
Bridgepoint Group plc
23 November 2022
 

Bridgepoint Group plc ("Bridgepoint" or the "Company")

 

Appointment of Cyrus Taraporevala as an Independent Non-Executive Director

 

23 November 2022

 

Bridgepoint is pleased to announce the appointment of Cyrus Taraporevala as an independent non-executive director, which will take effect from 1 January 2023. He will become a member of the Company's Remuneration and Audit and Risk Committees on the same date, and Carolyn McCall will step down as a member of the Remuneration Committee at that time.

 

Cyrus is a highly respected industry expert in asset management with more than 30 years of experience. He is the outgoing chief executive of State Street Global Advisors, the fourth largest asset manager globally, with $3.3 trillion under management.

 

Prior to joining State Street Global Advisors in 2016, he worked at several asset management firms: Fidelity Investments, BNY Mellon Asset Management, Legg Mason and Citibank. Earlier in his career he spent 14 years at McKinsey & Company, including 7 years as a partner.

 

Cyrus brings a unique mix of strategic perspectives and execution skills. A true citizen of the world, Cyrus has worked and lived in Asia, Europe and North America over the course of his career. He has successfully led and grown global businesses of scale and played a critical role in affirming State Street's reputation as both a stalwart and pioneer within the sector.

 

This appointment follows a search process conducted by the Bridgepoint Nomination Committee with the help of Russell Reynolds. Bridgepoint aims to make one further non-executive appointment during the course of 2023 to complete the construction of its Board of Directors.

 

Commenting on the appointment, Cyrus Taraporevala, said:

 

"Bridgepoint has achieved an impressive leadership position in the pan-European Alternative market and I'm excited to join the Board early in their journey as a listed business and to use my experience to help the team deliver on their growth objectives".

 

Commenting on the appointment, William Jackson, Executive Chairman, said:

 

"I am delighted that Cyrus is joining the Bridgepoint Board. We look forward to benefiting from his perspective on strategy and deep understanding of financial markets and the asset management industry, built up over his impressive 30-year global career. He will be a great addition to the Board as we continue to execute against the strategy outlined at IPO."

 

On 26 October 2022, it was announced that Cyrus had been appointed as a non-executive director of Shell plc, with effect from 2 March 2023. 

 

There are no other disclosures to make pursuant to LR 9.6.13 R.

 

 

ENQUIRIES

 

Bridgepoint

 

Analysts and investors

Adam Key

adam.key@bridgepoint.eu

+44 7833 748010

 

Media

Christian Jones / James Murray

christian.jones@bridgepoint.eu / james.murray@bridgepoint.eu

+44 20 7034 3500  

 

 

Finsbury Glover Hering (Public Relations Adviser to Bridgepoint)

 

Charles O'Brien / +44 20 7251 3801 / +44 7825 043656

Anjali Unnikrishnan / +44 20 7251 3801 / +44 7826 534233

Bridgepoint@fgsglobal.com 

 

 

Issued by Bridgepoint Group plc

LEI: 213800KFNMVI8PDZX472

Registered in England and Wales with registration number 11443992

Registered office: 5 Marble Arch, W1H 7EJ

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADLLFLLFLFFBD
Date   Source Headline
9th Jun 20267:00 amRNSHolding(s) in Company
12th May 20264:15 pmRNSResult of AGM
1st Apr 20264:00 pmRNSDirector/PDMR Shareholding
1st Apr 20264:00 pmRNSDirector/PDMR Shareholding
1st Apr 20267:00 amRNSTotal Voting Rights
26th Mar 202610:00 amRNSAnnual Report and Accounts and Notice of AGM
23rd Mar 202610:45 amRNSIssue of Equity and Total Voting Rights
16th Mar 202611:30 amRNSDirector/PDMR Shareholding
16th Mar 202611:30 amRNSDirector/PDMR Shareholding
16th Mar 202611:30 amRNSDirector/PDMR Shareholding
16th Mar 202611:30 amRNSDirector/PDMR Shareholding
12th Mar 20267:00 amRNSFinal Results
12th Mar 20267:00 amRNSFinal Results
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTotal Voting Rights
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
23rd Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:00 amRNSTransaction in Own Shares
19th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSTransaction in Own Shares
17th Feb 20267:00 amRNSTransaction in Own Shares
16th Feb 20267:00 amRNSTransaction in Own Shares
13th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 202612:30 pmRNSIssue of Equity and Total Voting Rights
12th Feb 20267:00 amRNSTransaction in Own Shares
11th Feb 20267:00 amRNSTransaction in Own Shares
10th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 202611:30 amRNSIssue of Equity
9th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20267:00 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSTransaction in Own Shares
30th Jan 20267:00 amRNSTransaction in Own Shares
29th Jan 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.